

References

I-232

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Viltolarsen (Viltepso) injection, for intravenous use [package insert]. NS Pharma, Inc. Paramus, NJ. Revised 08/2020.
3. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Viltolarsen.
4. Micromedex DrugDex Compendium®. 2020. Viltolarsen.
5. Birnkrant D, Bushby K, Bann C, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. 2018.
6. Birnkrant D, Bushby K, Bann C, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopedic management. *Lancet Neurol*. 2018.
7. Birnkrant D, Bushby K, Bann C, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol*. 2018.
8. Clemens P, Rao V, Connolly A, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to Exon 53 skipping: a phase 2 randomized clinical trial. *JAMA Neurol*. 2020.